28179308|t|Renieramycin M Attenuates Cancer Stem Cell -like Phenotypes in H460 Lung Cancer Cells
28179308|a|Cancer stem cells (CSCs) are a subpopulation of cancer cells that possess self-renewal and differentiation capacities. CSCs contribute to drug-resistance, cancer recurrence and metastasis, thus development of CSC -targeted therapeutic strategies has recently received significant attention in cancer research. In this study, the potential efficacy of renieramycin M (RM) isolated from the sponge Xestospongia species, was examined against lung CSCs. Colony and spheroid formation assays, as well as western blotting analysis of lung CSC protein markers were employed to determine the CSC -like phenotypes of H460 lung cancer cells after treatment with RM at non-toxic concentrations. RM treatment reduced significantly colony and spheroid formation of H460 cells. Moreover, the CSC markers CD133, CD44 and ALDH1A1 of CSC -enriched H460 cells were reduced significantly following RM treatment. RM could be a potent anti-metastatic agent by suppressing lung CSC -like phenotypes in H460 cells.
28179308	0	14	Renieramycin M	T109	C1435644
28179308	26	42	Cancer Stem Cell	T025	C1956422
28179308	49	59	Phenotypes	T032	C0031437
28179308	63	67	H460	T025	C0597032
28179308	68	72	Lung	T023	C0024109
28179308	73	85	Cancer Cells	T025	C0597032
28179308	86	103	Cancer stem cells	T025	C1956422
28179308	105	109	CSCs	T025	C1956422
28179308	134	146	cancer cells	T025	C0597032
28179308	160	172	self-renewal	T043	C1155711
28179308	177	192	differentiation	T043	C0007589
28179308	205	209	CSCs	T025	C1956422
28179308	224	239	drug-resistance	T038	C0013203
28179308	241	258	cancer recurrence	T191	C0920420
28179308	263	273	metastasis	T046	C4255448
28179308	280	291	development	T169	C1527148
28179308	295	298	CSC	T025	C1956422
28179308	309	331	therapeutic strategies	T061	C0087111
28179308	379	394	cancer research	T062	C1516225
28179308	404	409	study	T062	C2603343
28179308	425	433	efficacy	T080	C1280519
28179308	437	451	renieramycin M	T109	C1435644
28179308	453	455	RM	T109	C1435644
28179308	475	481	sponge	T204	C0032699
28179308	482	502	Xestospongia species	T204	C1204055
28179308	508	516	examined	T033	C0332128
28179308	525	529	lung	T023	C0024109
28179308	530	534	CSCs	T025	C1956422
28179308	536	572	Colony and spheroid formation assays	T059	C0005507
28179308	585	610	western blotting analysis	T059,T063	C0005863
28179308	614	618	lung	T023	C0024109
28179308	619	622	CSC	T025	C1956422
28179308	623	630	protein	T116,T123	C0033684
28179308	631	638	markers	T123	C0041365
28179308	670	673	CSC	T025	C1956422
28179308	680	690	phenotypes	T032	C0031437
28179308	694	698	H460	T025	C0597032
28179308	699	703	lung	T023	C0024109
28179308	704	716	cancer cells	T025	C0597032
28179308	723	732	treatment	T061	C0087111
28179308	738	740	RM	T109	C1435644
28179308	744	768	non-toxic concentrations	UnknownType	C0678563
28179308	770	772	RM	T109	C1435644
28179308	773	782	treatment	T061	C0087111
28179308	805	834	colony and spheroid formation	T059	C0005507
28179308	838	848	H460 cells	T025	C0597032
28179308	864	867	CSC	T025	C1956422
28179308	868	875	markers	T123	C0041365
28179308	876	881	CD133	T116,T123	C0673026
28179308	883	887	CD44	T116,T129	C1097299
28179308	892	899	ALDH1A1	T116,T126	C1721673
28179308	903	906	CSC	T025	C1956422
28179308	917	927	H460 cells	T025	C0597032
28179308	965	967	RM	T109	C1435644
28179308	968	977	treatment	T061	C0087111
28179308	979	981	RM	T109	C1435644
28179308	1000	1021	anti-metastatic agent	T121	C1516021
28179308	1037	1041	lung	T023	C0024109
28179308	1042	1045	CSC	T025	C1956422
28179308	1052	1062	phenotypes	T032	C0031437
28179308	1066	1076	H460 cells	T025	C0597032